Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIdE: Sacituzumab Govitecan in mTNBC
NCT05552001Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab govitecan in triple-negative breast cancer (TNBC), sponsored by Unicancer. Started Oct 2023; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05552001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05552001.